Valuation: Genelux Corporation

Market Cap 131M 115M 107M 98.46M 185M 12.56B 187M 1.27B 498M 6.2B 492M 481M 21.44B P/E 2026 *
-3.6x
P/E 2027 * -3.94x
Enterprise Value 131M 115M 107M 98.46M 185M 12.56B 187M 1.27B 498M 6.2B 492M 481M 21.44B EV / Sales 2026 *
-
EV / Sales 2027 * 10.8x
Free-Float
86.05%
Yield 2026 *
-
Yield 2027 * -
1 day+2.08%
1 week+0.68%
Current month-1.99%
1 month+2.79%
3 months+15.23%
6 months-0.34%
Current year-32.34%
1 week 2.85
Extreme 2.85
3
1 month 2.78
Extreme 2.775
3.18
Current year 2.29
Extreme 2.29
4.99
1 year 2.29
Extreme 2.29
8.54
3 years 1.6
Extreme 1.6
30.44
5 years 1.6
Extreme 1.6
40.98
10 years 1.6
Extreme 1.6
40.98
Manager TitleAgeSince
Chief Executive Officer 67 28/05/2014
Director of Finance/CFO 42 30/01/2025
Chief Tech/Sci/R&D Officer 55 01/05/2026
Director TitleAgeSince
Chairman 73 01/01/2014
Director/Board Member 68 01/09/2002
Director/Board Member 73 11/09/2023
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Sell

Director

-12,000 0.0268%
16/06/26 Free

Chief Executive Officer

730,601 1.6293%
16/06/26 Free

Chief Technology Officer

119,318 0.2661%
Change 5-day change 1-year change 3-year change Capi.($)
+2.08%+0.68%-11.68%-87.37% 131M
-0.63%+3.24%+53.34%+72.86% 56.19B
-0.27%+0.35%+40.26%+79.88% 54.83B
-2.05%-2.14%+0.75%+413.38% 22.7B
+1.97%-1.16%-21.00%-13.25% 23.04B
-0.21%-0.62%+20.56%-10.90% 20.23B
-1.38%+1.62%+25.71%-30.46% 17.83B
-0.97%-0.59%+33.12%+550.67% 15.65B
+5.29%+1.70%+185.09%+333.94% 15.24B
+0.79%+0.50%+22.39%+184.74% 14.03B
Average +0.47%+0.86%+34.85%+149.35% 23.99B
Weighted average by Cap. -0.01%+1.07%+38.62%+137.90%

Financials

2026 *2027 *
Net sales - 12.18M 10.71M 9.97M 9.16M 17.19M 1.17B 17.42M 118M 46.28M 577M 45.73M 44.74M 1.99B
Net income -37.1M -32.61M -30.36M -27.88M -52.35M -3.56B -53.04M -361M -141M -1.76B -139M -136M -6.07B -37.87M -33.29M -30.99M -28.46M -53.44M -3.63B -54.14M -368M -144M -1.79B -142M -139M -6.2B
Net Debt - -
Logo Genelux Corporation
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Employees
26
Date Price Change Volume
27/07/26 $2.950 +2.08% 66,498
24/07/26 $2.890 -2.36% 153,708
23/07/26 $2.960 0.00% 141,379
22/07/26 $2.960 +2.42% 108,167
21/07/26 $2.890 -1.37% 60,964
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.950USD
Average target price
17.50USD
Spread / Average Target
+493.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GNLX Stock